ImmVirX

ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need. ImmVirX was founded in late 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration – potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer. The ImmVirX team comprises key directors, executives and scientific staff from Viralytics. ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations. ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at The @Bell_Potter Healthcare Conference 2023 is now available. Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia. Leveraging our leadership and experience in oncolytic viral therapies, we are actively progressing clinical trials, based on a body of pre-clinical and manufacturing data developed since operations commenced in 2020.